AUPH Stock Overview
A biopharmaceutical company, focuses on delivering therapies to treat autoimmune diseases with unmet medical needs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Aurinia Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.44 |
| 52 Week High | US$10.67 |
| 52 Week Low | US$4.71 |
| Beta | 1.27 |
| 1 Month Change | 6.43% |
| 3 Month Change | -6.01% |
| 1 Year Change | 69.14% |
| 3 Year Change | -31.66% |
| 5 Year Change | -42.59% |
| Change since IPO | 311.71% |
Recent News & Updates
Results: Aurinia Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Mar 02
Aurinia Pharmaceuticals: There's Still Time For Sales Growth
Feb 21Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Held Back By Insufficient Growth Even After Shares Climb 25%
Dec 11Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
Nov 08Recent updates
Results: Aurinia Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Mar 02Aurinia Pharmaceuticals: There's Still Time For Sales Growth
Feb 21Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Held Back By Insufficient Growth Even After Shares Climb 25%
Dec 11Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
Nov 08Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Sep 06Aurinia Pharmaceuticals Appears Undervalued
Jul 05We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
May 24Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report
May 05Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
May 02Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Apr 18Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Mar 05Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
Feb 19Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues
Feb 17Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon
Feb 15Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential
Jan 28We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Jan 05Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price
Dec 18Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business
Sep 14Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement
Jun 11Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher
May 09We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
May 01Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%
Nov 04Shareholder Returns
| AUPH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.5% | -2.4% | -0.2% |
| 1Y | 69.1% | -6.8% | 8.1% |
Return vs Industry: AUPH exceeded the US Biotechs industry which returned -6.8% over the past year.
Return vs Market: AUPH exceeded the US Market which returned 7.9% over the past year.
Price Volatility
| AUPH volatility | |
|---|---|
| AUPH Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AUPH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AUPH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 130 | Peter Greenleaf | www.auriniapharma.com |
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, focuses on delivering therapies to treat autoimmune diseases with unmet medical needs in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases.
Aurinia Pharmaceuticals Inc. Fundamentals Summary
| AUPH fundamental statistics | |
|---|---|
| Market cap | US$1.16b |
| Earnings (TTM) | US$5.75m |
| Revenue (TTM) | US$235.13m |
201.5x
P/E Ratio4.9x
P/S RatioIs AUPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AUPH income statement (TTM) | |
|---|---|
| Revenue | US$235.13m |
| Cost of Revenue | US$49.03m |
| Gross Profit | US$186.10m |
| Other Expenses | US$180.35m |
| Earnings | US$5.75m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.042 |
| Gross Margin | 79.15% |
| Net Profit Margin | 2.45% |
| Debt/Equity Ratio | 0% |
How did AUPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 02:52 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aurinia Pharmaceuticals Inc. is covered by 22 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Dae Gon Ha | BTIG |
| Neil Maruoka | Canaccord Genuity |